CHMP recommends Minoryx’s ALD drug, rejects Zevra’s Meplyffa
CHMP recommends Minoryx’s ALD drug, rejects Zevra’s Meplyffa.
Minoryx Therapeutics
Private
Minoryx Therapeutics is a clinical-stage biotechnology company developing differentiated therapies for X-linked adrenoleukodystrophy (X-ALD) and other orphan CNS diseases. Its lead candidate, leriglitazone, is an oral, brain-penetrant PPAR-γ agonist for cerebral ALD and Friedreich's ataxia.